Interventional Oncology Market: Analysis & Forecast To 2026 By Key Players, Share, Trend, Segmentation
                     MarketsandMarkets 
Presents
Interventional Oncology Market worth $2.9 billion by 2026
https://www.marketsandmarkets.com/Market-Reports/interventional-oncology-market-2036
87164.html
The report "Interventional Oncology Market by Product (Radiofrequency, microwave, 
embolization, guidewires), Procedure (Thermal, Non-Thermal Ablation, TACE, TARE, 
TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis), Enduser (Hospital, ASC) - Global 
Forecast to 2026" The global interventional oncology market size is estimated to be 
USD 1.9 billion in 2020 and is projected to reach USD 2.9 billion by 2026, at a CAGR of 
6.8%. 
The increasing prevalence of diseases and disorders, technological advancements, and 
increased funding and public-private investments are the key factors driving the 
growth of the interventional oncology market.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownload
Objectives of the Study:
• Demand for embolization devices result in the segment occupying the high share of 
the interventional oncology market
• Liver cancer estimated to be the growing market
Liver cancer accounted for the largest share of the interventional oncology 
market in 2020. Interventional oncology plays a crucial role in treating liver 
cancer, as removing the tumor with surgery may not leave the tissue healthy 
enough for effective liver functioning. Thus, primary liver tumors or liver tumors 
resulting from metastatic cancers can effectively be treated using interventional 
oncology procedures. Owing to this, more than half of all treatments for primary 
and metastatic liver cancer are conducted using interventional oncology.
• Asia Pacific likely to emerge as the fastest-growing interventional oncology market, 
globally
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalyst
This research report categorizes the interventional oncology market 
based on product, procedure, cancer type, end user, and region.
By Product
• Embolization Devices
• Ablation Devices
• Support Devices
By Procedure
• Thermal Tumor Ablation
• Non-Thermal Tumor Ablation
• Transcatheter Arterial Chemoembolization
• Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
• Transcatheter Arterial Embolization/Bland Embolization
By Cancer Type
• Liver Cancer
• Lung Cancer
• Bone Metastasis
• Kidney Cancer
• Breast Cancer
• Prostate Cancer
• Other Cancers
Medtronic, Boston Scientific, BD, Terumo, Merit Medical, AngioDynamics, J&J, Teleflex, 
Cook Medical, HealthTronics, MedWaves, Sanarus, IMBiotechnologies, Trod Medical, 
IceCure Medical, Mermaid Medicals, Interface Biomaterials BV, Guerbet, ABK 
Biomedical, Shape Memory Medical, Endo Shape, Monteris Medical, Instylla, Trisalus 
Lifesciences, Profound Medical Corp, Sirtex, Accuray, Baylis Medical, and ALPINION 
MEDICAL SYSTEMS and Among Others
Companies Insight
Boston Scientific (US) dominated the global interventional oncology market in 2020. The 
company mainly focuses on growth strategies such as acquisitions and expansions to increase its 
market presence and product offerings. The company’s plan to acquire BTG will help expand its 
product offerings in chemoembolization, radioembolization, and ablation therapies. Boston 
Scientific constantly strives to gain regulatory and reimbursement approvals. As a part of its 
long-term growth strategy, the company invests in fast-growing markets as well as new markets 
by strengthening its position in the global healthcare market.
Medtronic (Ireland) held the second position in the global interventional oncology market in 
2020. The company focuses on adopting various organic growth strategies like product launches 
& approvals and inorganic growth strategies, such as acquisitions and collaborations, to expand 
its presence and share in the interventional oncology market. In line with this, the company 
launched various tumor management products like OptiSphere Embolization Spheres and 
OsteoCool Rf Ablation Systems and received US FDA clearance, which helped it to expand its 
presence in the market.
Contact Us
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road, Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
Press release:
https://www.marketsandmarkets.com/PressReleases/interventional-o
ncology.asp
Research insights:
https://www.marketsandmarkets.com/ResearchInsight/interventional
-oncology-market.asp
About MarketsandMarkets
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche 
opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. 
Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 
companies as clients. Almost 75,000 top officers across eight industries worldwide 
approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high 
growth markets following the "Growth Engagement Model – GEM". The GEM aims at 
proactive collaboration with the clients to identify new opportunities, identify most 
important customers, write "Attack, avoid and defend" strategies, identify sources of 
incremental revenues for both the company and its competitors. MarketsandMarkets™ 
now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, 
emerging companies, innovators, strategic players) annually in high growth emerging 
segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies 
this year for their revenue planning and help them take their innovations/disruptions 
early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, 
"RT" connects over 200,000 markets and entire value chains for deeper understanding 
of the unmet insights along with market sizing and forecasts of niche markets.